Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study
Background: Cytoreductive therapies have been the standard treatment for patients with high-risk polycythemia vera (PV) for decades. However, approximately 24% of patients treated with hydroxyurea will eventually develop resistance or intolerance to hydroxyurea and need second-line (2L) therapy. Obj...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-07-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/20406207251342199 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|